)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Camurus
Camurus (CAMX) investor relations material
Camurus Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Record Q3 revenue of SEK 724m, up 28% YoY, and operating result of SEK 322m, up 40%; no milestone revenue was recorded in the quarter.
Record product sales of SEK 582m were led by Buvidal; Brixadi royalties grew, and quarter-end cash was SEK 4,353m.
FDA review of the CAM2029 acromegaly NDA resubmission and Oczyesa approvals in Australia and Canada advanced the pipeline.
Financial highlights
Q3 product sales were SEK 582m, including Buvidal at SEK 574m and Oczyesa at SEK 8m; royalties were SEK 137m.
Operating expenses rose 20% YoY to SEK 356m; R&D costs increased to SEK 142m, mainly reflecting SORENTO progress.
9M revenue was SEK 1,959m and operating result SEK 783m; excluding Lilly license revenue, 9M revenue grew ~13% and operating result ~14%.
Q3 profit before tax was SEK 341m and net income SEK 270m; diluted EPS was SEK 4.53 vs. SEK 3.24 a year earlier.
Outlook and guidance
FY 2026 revenue guidance remains SEK 2.6bn–2.9bn and operating result SEK 0.9bn–1.2bn; both are expected in the upper half of the ranges.
2026 incremental U.S. launch-related spend is now ~SEK 100m vs. SEK 200m planned; additional R&D spend is ~SEK 50m vs. SEK 150m, with deferred spend moving to 2027.
2027 operating margin was framed at 44%–50%; reaching 50% may be difficult as U.S. expansion and R&D investment increase.
SORENTO topline results are expected in Q1 2027; CAM2056 Phase 2b obesity study results are expected in H1 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Camurus
- Buvidal growth and late-stage pipeline progress support a strong outlook.CAMX
Company presentation - Buvidal growth and pipeline progress support a strong 2025 outlook.CAMXAGM 2025 presentation
- Commercial growth and three potential 2026 catalysts underpin the next stage of expansion.CAMXAGM 2026 presentation
- Buvidal and Brixadi expand as CAM2029 approaches key regulatory milestones.CAMXCompany presentation
- Growing opioid-treatment sales and advancing CAM2029 toward multiple potential approvals.CAMXCompany presentation
- Buvidal growth and positive CAM2029 results underpin strong FY 2025 guidance.CAMXCompany presentation
- Buvidal growth and CAM2029 milestones drive the 2024–25 expansion agenda.CAMXCompany presentation
- Buvidal growth and CAM2029 milestones anchor a five-fold revenue ambition for 2027.CAMXCompany presentation
- Buvidal growth and CAM2029 progress support expansion and FY2025 growth guidance.CAMXCompany presentation
Next Camurus earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
Camurus
Next Camurus earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Camurus is a pharmaceutical company that develops and commercializes long-acting treatments for serious and chronic conditions. The company specializes in proprietary drug delivery technologies, particularly its FluidCrystal system, which is designed to provide extended drug release through subcutaneous or intramuscular injection. Camurus focuses on areas such as opioid dependence, pain management, oncology, and endocrinology, aiming to improve treatment adherence and patient outcomes. Its product portfolio includes both commercialized therapies and development-stage programs across multiple therapeutic areas. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.